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Enhanced solubility and dissolution, improved bioavailability
and absorption, elimination of food effects, safe dose escala-
tion, enhanced safety, efﬁcacy and tolerability proﬁles are
the inherited advantages of nanoparticles due to their size
and surface features. Drug nanocrystals (NCs) are the nano-
particles which offer an additional advantage of 100% drug
loading since they are encapsulating-carrier free nanoparticles.
An NC formulation contains drug and one/more stabilizers
dispersed in aqueous or non-aqueous media. Stabilizers could
be one or more generally regarded as safe excipients (surfac-
tants or buffers, salts or sugars). The liquid dispersion NCs
could be further post processed into solid or sterile injectable
dosage forms (Merisko-Liversidge and Liversidge, 2008). The
therapeutic applications of NC products have been identiﬁed
in oral (Hanafy et al., 2007; Kayser et al., 2003; Mauludin
et al., 2009), parenteral (Ganta et al., 2009; Rabinow et al.,
2007; Gao et al., 2008), ocular (Kassem et al., 2007; Ali
et al., 2011), dermal (Shaal et al., 2011; Mitri et al., 2011;
Mishra et al., 2009), pulmonary (El-Gendy et al., 2011;
Jacobs and Mu¨ller, 2002; Yang et al., 2010) and targeted drug
delivery (Kayser et al., 2001; Muller and Jacobs, 2002). NCs,
further offer ﬂexibility of upscaling and downscaling which
could be of great value whenever alterations with respect to
unit operation functions or formulation are desired during
scaling up process (Eerdenbrugh et al., 2009). The formulation
simplicity and production scaling ﬂexibility along with their
intrinsic small particle size and large surface area make NCs
stand a way unique not just among the pharmaceuticals but
also among other nanoparticles.
There are already six licensed and regulatory approved NC
products launched in the market. Products like Semapimod
(guanylhydrazone), Paxceed (paclitaxel), Theralux (thy-
mectacin) and Nucryst (silver) are currently under clinical
phases and there are many more products under preclinical
stages (Gasper, 2010). Each of the commercialized NC prod-
ucts represents a rational formulation design. Rapamune
was developed as a tablet dosage form to overcome the unpal-
atable taste and restricted cold storage conditions of the earlier
formulation of sirolimus (rapamycin). Drug absorption being
effected by food uptake was the disadvantage encountered
by the then existing formulation of aprepitant. Emend was
developed using nanosuspension of aprepitant and was formu-
lated as a spray coated solid capsule dosage form which exhib-
ited enhanced bioavailability due to reduced fast and fed state
variations. TriCor and Triglide are tablet formulations of
fenoﬁbrate designed to improve the bioavailability and to
overcome the fast and fed state dependent absorption varia-
tions associated with other formulations of this drug. Megace
ES is a liquid dispersion dosage form designed to improve
dissolution, and bioavailability of megestrol acetate and
thereby provides reduced dosing volume compared to other
dosage forms of the drug. Invega Sustenna was developed
as a once monthly extended release sterile injectable liquid dis-
persion dosage form of paliperidone palmitate (intramuscular
suspension) available in preﬁlled syringes and it stands unique
for being available at variable dose strengths with a two year
shelf life period. The patient population to whom paliperidone
palmitate (antipsychotic) is indicated pose compliance prob-
lems to a great extent and the NC product being a once amonth administrable medicine scores for its patient friendly
therapy (Merisko-Liversidge and Liversidge, 2011; Shen and
Wu, 2007; Wu et al., 2004; Eerdenbrugh et al., 2008;
Deschamps et al., 2009). On account of such rational formula-
tion development, an NC is considered as a new drug product
by Food and Drug Administration (FDA) and not as a ‘‘gen-
eric’’ to any other approved product since its pharmacokinetic
proﬁle is not bioequivalent to any other solubilized form of the
same drug, not even to the drug’s own micronized form,
administered at the same dosage. Therefore, an NC could be
patented as ‘‘new drug’’ which offers a product line extension
for the already existing drug formulations and could serve as a
new and beneﬁcial dosage form (Singare et al., 2010).
2. Preparation and characterization of drug nanocrystals
Before delving into the discussions on scale up based research
works, a snapshot of typical manufacturing methods available
for the production of NCs has been provided. The preparation
techniques for NCs could be mainly classiﬁed into three
categories namely top down, bottom up, and combination
methods. A detailed description of the classiﬁed methods as
well as of the possible sub classiﬁcations under each of the clas-
ses has already been elucidated by various authors (Patravale
et al., 2004; Kocbek et al., 2006; Zhang et al., 2011; Chan
and Kwok, 2011). In short, the top down methods are physico-
mechanical processes mainly involving crushing or attrition
principles (fragmentation) while bottom up methods are phys-
icochemical processes involving the principles of atomic or
molecular level self organization (amalgamation) as demon-
strated in Fig. 1. The top down methods mainly involve milling
or homogenization while the bottom up methods are primarily
based on the principle of precipitation. The combination
approaches involve bottom up plus top down method
combinations.
Wet ball milling comminutes material loaded into milling
chamber with an agitator (milling media). The milling mate-
rial, the drug to be nanosized is normally provided as a treated
(micronized) or untreated solid dispersed in a liquid medium
(usually water) with the aid of surfactants as stabilizers. The
comminution principle involved is the mechanical attrition
and shear that arises due to collision between milling media
and drug particles or between two drug particles or also
between a drug particle and the walls of the milling chamber.
The milling media are small beads or pearls made of ceramic
(e.g., yttrium stabilized zirconium dioxide) or highly cross-
linked polystyrene resin or stainless steel or glass having differ-
ent sizes (0.3 mm or higher). However, the ﬁrst two ensure
minimal contamination to the product. The size reduction
effectiveness could be further determined by the concentration
of drug and surfactant, viscosity of the dispersion medium,
temperature conditions and by the initial particle size and
hardness of the drug (Niwa et al., 2011; Mo¨schwitzer, 2013;
Gao et al., 2008; Merisko-Liversidge and Liversidge, 2011).
HPH is another top down process where in the particle size
reduction is brought about by shear forces, cavitation forces
and particle collision aided by high pressure conditions. It is
of two types namely the microﬂuidization and piston gap
homogenization. Microﬂuidization is also called as air-jet mill-
ing or jet stream homogenization wherein the particles are
fragmented in a high pressure air jet induced by collision of
Figure 1 Production of drug nanocrystals.
Drug nanocrystals 389two ﬂuid streams. Piston-gap homogenization employs high
pressure to force a liquid suspension through a gap or narrow
channel inside a pipe. If the medium is aqueous, bubbles are
formed inside the gap due to reduced static pressure in the
gap region which later collapse upon exiting the narrow gap.
The break-up of particles is achieved by the consequently gen-
erated cavitation energy. On the other hand if the medium is
oil or a non aqueous solvent, the particle comminution is facil-
itated by the high shear and collision through the gap
(Shegokar and Mu¨ller, 2010; Mu¨ller et al., 2001; Keck et al.,
2008; Keck and Mu¨ller, 2006).
All bottom up approaches employ two basic principles
namely precipitation and evaporation. Accordingly there are
numerous variations available which incorporate either of
the two principles or a combination of both. ‘Cryogenic sol-
vent evaporation’ is a bottom up method which involves spray-
ing of drug solution into cryogenic liquids using ‘spray freezing
into liquid’ technology. Here the drug solution droplets are
frozen upon contact with cryogenic liquid (liquid nitrogen)
and the organic solvent is removed by lyophilization. Precipi-
tation when performed in conjugation with centrifugation is
termed ‘high gravity controlled precipitation’ technique. Per-
forming precipitation at elevated temperatures is called ‘evap-
oration precipitation into aqueous solution’. A technique such
as ‘controlled crystallization during freeze drying’ is also avail-
able. There are several methods involving precipitation based
on supercritical ﬂuid (SCF) technology. If the drug is soluble
in SCF, the method employed is called ‘rapid expansion of
supercritical solution’. If SCF is used as antisolvent, there
are other variations possible such as ‘gas antisolvent process’,
‘supercritical antisolvent process’ and ‘solution enhanced dis-
persion of solids’. Each of the different variations was dis-
cussed extensively by a few authors. Literature presents the
reports of some positive results with the specialized bottom
up approaches too but their application is mainly limited
due to the requirement of special processing expertise andcustom designed equipment as well as the high costs associated
with such production equipment. Solvent–antisolvent precipi-
tation is the simplest and single step precipitation process
involving low energy, less expense and requires simpler instru-
ments. The process may be designed more efﬁciently with the
incorporation of high speed homogenization or sonication
and subsequent solidiﬁcation. The use of evaporation pro-
cesses like spray or freeze drying operable at low temperatures
(suitable for thermolabile drugs) or ﬂuid bed drying for solid-
iﬁcation purpose would still constitute cost-efﬁcient processes
when compared to other high energy and sophisticated precip-
itation processes (Mo¨schwitzer, 2013; Abdelwahed et al., 2006;
Chan and Kwok, 2011; Sinha et al., 2013).
All the combination approaches are uniquely referred to as
smartCrystals (Keck et al., 2008; Shegokar and Mu¨ller,
2010). Examples of smartCrystals technologies so far
explored include Nanoedge technology which involves
microprecipitation plus high pressure homogenization (HPH)
(Kipp, 2004); H42 technology involving non-aqueous spray
drying followed by HPH (Salazar et al., 2013); H96 technology
which involves freeze-drying followed by HPH (Salazar et al.,
2012). There is also one H69 technology which employs the
same combination approach as Nanoedge but in order to
save time between the precipitation and homogenization pro-
cesses and to yield smaller drug NCs, the precipitation process
is carried out directly within the zone of dissipation of homog-
enizer (Kakrana et al., 2012). Combination Technology (CT) is
another smartCrystal technology which involves media milling
followed by high pressure homogenization (Shaal et al., 2010).
A brief summary of the most commonly employed character-
ization methods for NC products is presented in Table 1.
3. Scale up
Scale up with respect to pharmaceutical manufacturing process
is a translation involving the transformation from microscopic
Table 1 Most commonly employed characterization techniques for nanocrystals (Singare et al., 2010; de Waard et al., 2009; Shaal
et al., 2010; Hu et al., 2011; Niwa et al., 2011; Shegokar et al., 2011; Quan et al., 2011; Ghosh et al., 2012; Mo¨schwitzer, 2010a,b).
Characterization
parameter
Examples of analytical methods
Structure and
morphology
Light microscopy, scanning electron microscopy, transmission
electron microscopy, ﬁeld emission scanning electron microscopy,
atomic force microscopy
Particle size and particle
size distribution
Photon correlation spectroscopy (based on dynamic laser light
scattering), laser diﬀraction (static laser light scattering),
microscopic methods
Surface charge Zeta potential
Solid state analysis
(crystallinity)
Powder X-ray diﬀraction, diﬀerential scanning calorimetry
Rheological properties
(for liquid
nanosuspensions)
Viscometer, rheometer
390 K.M. Raghava Srivalli, B. Mishra(molecular) lab level to macroscopic (bulk) industrial commer-
cial level production. Operationally scale up ratio is deﬁned as
follows:
Scale up ratio = large scale production rate/small scale
production rate
However, in literal sense, scale up is a process which could
not be detailed by such a simple ratio. The design and develop-
ment of scale up is emphasized because there is no framed
algorithm which can help the formulators predict the large
scale performance of a product based on its small scale behav-
ior. Scale up is accomplished by the sameness criterion, the
sameness among all the three levels of study, lab, pilot and
the production. At each of the three levels, the raw material
speciﬁcations and controls, in process and ﬁnished product
speciﬁcations and bioequivalence results of any given lot are
expected to be in line with the results of previous lots (Levin,
2002). Fig. 2 depicts the similarity concerns to be born on mind
while planning a scale up.
The success of any formulation development depends on its
transferability to large scale and all the NC products already in
the market might have been designed by keeping on mind, the
industrial production ever since their lab scale development.
Additionally, a scalable formulation/method will remain robust
at all the three levels of study, the lab, pilot and industry. Based
on the above fact, our interest arose in reviewing the efforts
involved in scale up based research works since we believe that
the study of success proﬁles of scalable formulations/methodsFigure 2 Set of product attributes whose similarity is critical
during a scale up process.may increase the early optimization rates of the beginners in
the ﬁeld. Literature shows that there are a few such researches
on NCs. Table 2 lists the summary of such works. Our present
paper presents a note on all the listed research works as case
studies. Each of these works either had scalability as their objec-
tive or upscaling as their future scope.4. Case studies
A survey on the recent publications reveals the vivid shift of
the research on drug NCs from the stage of lab level optimiza-
tion to the stage of upscaling studies. This shift is certainly
encouraging on account of the advantages offered by these
particular delivery systems and as such, a review of such NC
upscaling studies has been incorporated in this paper. The fol-
lowing sections provide a thorough review of the research
works with scalability as objective or upscaling as future scope.
In order to avoid a monotonous brief or gist of the research
works and by bearing reader’s convenience on mind, our
understanding of each of the research works was presented
in ﬁve sections to cover the process (method), equipment,
formulation, stability and summary of the works.
4.1. Batch and semi-continuous production of nanocrystals by
controlled crystallization using a ‘3-way nozzle equipment’
(de Waard et al., 2009)
The authors of this research work carried out the NC produc-
tion in batch fashion as well as in semi-continuous fashion
using a ‘3-way nozzle equipment’ with large scale production
potential. The actual process involved initial mixing of the
solution of drug (fenoﬁbrate) in tertiary butyl alcohol (TBA)
with the solution of cryoprotectant (mannitol) in water and
the subsequent freeze drying at a relatively high temperature
(25 C). The immediate freezing was employed since the
mixture of the above two solutions was thermodynamically
unstable by being prone to premature crystallization of
the drug which may result in the formation of large drug
crystals.
During batch production, just the moment the solutions
were mixed manually, the vials were immersed in liquid
nitrogen. In order to design a semi-continuous production
Table 2 Examples of scale up based research works on nanocrystals.
Active/actives Method Media Stabilizer/stabilizers Refs.
Fenoﬁbrate Controlled crystallization during
freeze-drying (made semi-continuous
process by applying a 3-way nozzle)
Active in tertiary butyl
alcohol and excipients in
water
Matrix material, mannitol de Waard et al. (2009)
Meloxicam Media milling (and subsequent spray
drying for characterization)
Water Hydroxylpropyl methyl cellulose
and sodium lauryl sulfate
Singare et al. (2010)
Apigenin
(ﬂavonoid)
Media milling and subsequent high
pressure homogenization
(smartCrystal combination
technology – CT)
Water Plantacare 2000 (alkyl
polyglycoside)
Shaal et al. (2010)
Fenoﬁbrate Antisolvent precipitation coupled
with immediate spray drying
Active in ethanol and
excipients in water
Hydroxylpropyl methyl cellulose
and sodium dodecyl sulfate
Hu et al. (2011)
Phenytoin,
pranlukast hydrate
and nifedipine
Media milling (and subsequent
freeze drying for characterization)
Water Polyvinyl pyrrolidine and sodium
lauryl sulfate
Niwa et al. (2011)
Nevirapine Comparison of high pressure
homogenization and media milling
(and subsequent air drying for
characterization)
Water Polyvinyl pyrrolidine, poloxamer
188, tween 80, volpoL4, and
plasdone
Shegokar et al. (2011)
Nitrendipine Precipitation-homogenization
combination and further spray
drying
Active in acetone and
excipients in water
Polyvinyl alcohol Quan et al. (2011)
NVS-102 (model
drug)
Media milling (and subsequent
freeze drying for characterization)
Water D-a-tocopheryl polyethylene
glycol 1000 succinate and
hydroxylpropyl methyl cellulose
Ghosh et al. (2012)
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studied. A nozzle was designed with three separate channels
for aqueous solution, TBA-solution, and atomizing air ﬂow
in such a way that the atomizing air thoroughly mixes the
two solutions as soon as they leave the nozzle. The resulting
mixture was then immediately frozen by spraying it directly
into liquid nitrogen to prevent premature crystallization. This
semi-continuous design provided a more instantaneous freez-
ing since the atomizing air produced small droplets of mixture
and resulted in smaller drug crystals with superior drug release
proﬁles which indicates the success of the semi-continuous
design for the production of better controlled crystallized dis-
persions and its suitability to large scale production.
The immediate freezing further to mixing was carried out at
a temperature below the glass transition temperature and the
subsequent freeze drying was carried above the glass transition
temperature but below the eutectic temperature. Such temper-
ature conditions lead to the crystallization of the drug and
matrix material in the freeze-concentrated fraction and the
crystal size was found to be affected by the freezing rate and
water/TBA ratio. The immediate freezing requirement at the
large scale was aimed to be achieved by using the 3-way nozzle
model designed in this study. The mixing efﬁciency of the
3-way nozzle model was studied to validate the upscaling suit-
ability of controlled crystallization process from batch to semi-
continuous state. Additionally, the crystallinity and
dissolution performance of the controlled crystallized disper-
sions prepared by the batch process and the semi-continuous
process were compared.
A method by name Villermaux/Dushman originally devel-
oped for microﬂuidic devices to measure the mixing quality,
was used to validate the mixing efﬁciency of the 3-way nozzle
model. The method involved mixing of an acidic and a
buffered iodine/iodate solution which can trigger two parallelreactions depending on the mixing quality. A slow mixing leads
to the formation of triiodine out of acid and a fast mixing leads
to neutralization of acid by the buffer (here no triiodine was
formed). Hence the triiodine amount formed was used as a
measure for mixing efﬁciency and a mixing of poor quality
could be indicated by the formation of triiodine due to reaction
of some amount of acid with iodine and iodate, which may be
detected using a spectrophotometer. The Villermaux/Dushman
method was applied to the 3-way nozzle model with and with-
out (control) application of atomized air. The spray settings
tested were similar to those used for spray freeze drying of con-
trolled crystallized dispersion by setting the rate of atomizing
air ﬂow at 500 L/h (i.e. 500 L of air at 1 atm and 0 C), a total
liquid ﬂow as 15 ml/min and the distance to the sprayed surface
as 60 mm. A lower spectroscopic absorption indicates forma-
tion of less triiodine, in other words indicates faster and better
quality mixing. The spectroscopic absorption was much lower
(0.222 ± 0.06) for the 3-way nozzle sample produced with the
atomizing airﬂow rate of 500 L/h when compared to the sample
(1.163 ± 0.08) produced as control without applying the atom-
izing airﬂow (for control, the drug and mannitol solutions were
mixed without aid of atomizing air ﬂow by adapting Villerm-
aux/Dushman method). Hence the spectrophotometric results
conﬁrmed a proper degree of mixing of two solutions in the pres-
ence of atomizing air which validates the use of the 3-way nozzle
model for a homogenous mixing of the aqueous-mannitol and
TBA-drug solutions to produce a controlled crystallized disper-
sion. Based on the dissolution results, the authors conﬁrmed
that the semi-continuous design was valuable for large scale
production and yields a better product.
4.1.1. Process
The aqueous-mannitol and TBA-drug solutions were preheated
to 60 C before subjecting to the batch or semi-continuous
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aqueous-mannitol and TBA-drug solutions were respectively
mixed in 20 ml glass vials and the vials were immediately
immersed in liquid nitrogen and subsequently freeze dried. In
case of semi-continuous process, the preheated aqueous-
mannitol and TBA-drug solutions were pumped separately
using perfusion pumps through a heated 3-way nozzle at a ﬂow
rate of 9 and 6 ml/min. respectively. The total liquid volumes of
55, 70, and 90 ml were mixed to achieve drug loads of 30%,
40%, and 50% (w/w), respectively. The liquid dispersion
obtained by the mixing of two solutions was then sprayed
directly with the aid of atomized airﬂow, into liquid nitrogen
ﬁlled metal tray. Thus frozen material was subsequently freeze
dried. During freeze drying, the temperature of samples was ini-
tially equilibrated on a pre-cooled shelf (50 C) for 1.5 h and
the subsequent increase in temperature to 25 C crystallized
the drug and matrix material. Next, the solvents were removed
by decreasing the pressure to 0.220 mbar after 3 h. This low
pressure was maintained for 10 h after which the temperature
was gradually increased to 20 C. The samples were stored at
room temperature for at least 1 day in a dessicator over silica
gel before further processing.
4.1.2. Equipment
The semicontinuous process employed a custom designed
3-way nozzle model and the freeze drier used was Christ model
Epsilon 2–4 lyophilizer (Salm en Kip, Breukelen, The
Netherlands).
4.1.3. Formulation
25 mg/ml of drug in TBA solution was mixed with varying con-
centrations of mannitol in water so as to produce drug loads of
30%, 40%, and 50% (w/w) at both batch and semi-continuous
levels. The scanning electron microscopy (SEM) pictures
though showed the presence of aggregates, the particles size
(PS) values were less than 1 lm (nanorange). The controlled
crystallized dispersions produced by batch and semi-continuous
processes were tested for their crystallinity and dissolution
characteristics. The differential scanning calorimetric (DSC)
analysis showed that the degree of crystallinity for the products
produced by batch (86–93%) and semi-continuous (82–86%)
processes was similar. Tablets were prepared with physical mix-
ture containing 30% fenoﬁbrate, 30% controlled crystallized
product produced by batch process (freeze-dried) and semi-
continuous process (spray freeze-dried) and their dissolution
proﬁles were compared. The results indicated that the tablets
prepared from the controlled crystallized dispersions irrespec-
tive of the batch and semi-continuous process involved, showed
identical drug release proﬁles (almost 100% drug dissolved in
2 h) while the tablets prepared with physical mixtures released
lower drug amounts (less than 50% drug dissolved in 2 h).
The dissolution rate of the tablets containing controlled crystal-
lized dispersion prepared by semi-continuous process was
slightly higher than the batch-wise produced product on
account of the higher freezing rate and smaller drug NCs pro-
duced during semi-continuous process. Additionally, the effect
of drug load on the dissolution rate was studied which showed
that the increase in drug loads from 30% to 40% and 50%
decreased the dissolution rate for which the authors reasoning
was that for a ﬁxed mass of tablet, with the increase in drug
concentration, the lipophilicity increased which resulted indecreased wetting and consequently decreased dissolution rate.
Besides, with the increasing drug loads, the difference in the
release proﬁles (rate and extent of drug dissolved) of batch
process product and semi-continuous process product also
increased.
4.1.4. Stability
The controlled crystallized dispersions were prepared by using
d-mannitol which has a reported stability for few years at
ambient conditions. So the authors claimed that the shelf life
problems need not be expected for the prepared controlled
crystallized dispersions.
4.1.5. Summary
A scalable semi-continuous equipment model was designed for
the production of drug NCs. The NC production was carried
out in batch and semi-continuous fashions and the study
designed a new ‘3-way nozzle equipment’ with large scale pro-
duction potential for the semi-continuous production. The
mixing efﬁciency of the 3-way nozzle model was validated
using Villermaux/Dushman method. The NCs were ﬁnally
formulated as tablet dosage forms and the release studies dem-
onstrated higher dissolution of the tablets prepared out of the
3-way nozzle manufactured NCs as compared to those of
batch model.
4.2. Application of design of experiments to optimize the
production of a nanosuspension formulation with an industrial
perspective (Singare et al., 2010)
Box–Behnken design was applied to study the effect of formu-
lation and processing parameters on the PS, zeta potential
(ZP) and scalability of formulation. The model drug chosen
for study was meloxicam. The optimization of formulation
variables can render a robust and stable formula with ideal
characteristics and the processing parameters can affect the
production of nanosuspension at large scale.
4.2.1. Process
Top down media milling was the production process chosen.
Puriﬁed water, yttrium-stabilized zirconium beads and
0.2 mm as bead volume were screened during the initial screen-
ing studies as the solvent for nanosuspension production, the
media for milling and the milling media volume, respectively.
A recirculation mode of milling operation was performed with
the pump/ suspension fed rate as 100 ml/min. The product
temperature was controlled by circulating cold water through
the outer jacket during milling. 250 g batch size, 16 g drug con-
tent, the type of polymer and stabilizer were kept constant
throughout the study. The polymer used was hydroxyl
propylmethyl cellulose (HPMC), 6 cps and the stabilizer was
sodium lauryl sulfate (SLS).
Based on the screening studies, the parameters inﬂuencing
ZP and the mean PS, d(90) of formulation were ﬁltered as
the ratio of polymer to drug, ratio of stabilizer to drug, milling
time and milling speed. Hence, the process was characterized
by studying the effect of the above formulation variables and
processing parameters on ZP and PS. A premixed product
was subjected to milling and as far as the production process
was concerned, both the ZP and PS were found to be
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follows. Lower milling speeds decreased ZP while the effect of
milling time was not clariﬁed. Particle size decreased with
increasing milling speeds and time. The required ZP in the
range of 20 to 25 mV and d(90) values of 350–400 nm were
achieved by optimizing the milling time for 3.8 h and milling
speed at 2563 rpm.
4.2.2. Equipment
The equipment chosen was bead mill, Model: Lab Star 1,
Netzsch Mill, Germany to produce 250 g batches at lab scale.
4.2.3. Formulation
The effect of formulation variables namely polymer to drug
ratio and surfactant to drug ratio on ZP and particle size,
d(90) were evaluated. The polymer to drug ratio signiﬁcantly
inﬂuenced the ZP rather than the surfactant to drug ratio.
High polymer concentrations decreased the ZP values indepen-
dent of the surfactant to drug ratio. The PS was low at lower
polymer concentrations. A ZP range from 20 to 25 mV and
d(90) of 350–400 nm were achieved by optimizing the polymer
to drug and surfactant to drug weight ratios at 0.39 and 0.04,
respectively, as understood from the optimized formula. The
optimized formula contained 16 g drug, 3.9 g polymer and
0.4 g surfactant dispersed in 250 ml water. The spray dried
product was subject to X-ray diffraction (XRD) which con-
ﬁrmed retention of solid state characters.4.2.4. Stability
The stability study was not performed in the above research
work.
4.2.5. Summary
The wet ball milling process for the production of meloxicam
nanosuspensions was characterized by studying the effect of
the above formulation variables and processing parameters
such as ratio of polymer to drug, ratio of stabilizer to drug,
milling time and milling speed on ZP and PS of formulation.
The authors successfully utilized the Box–Behnken design,
ANOVA, perturbation plots, research surface methodology
and contour graphs to study the effect of the independent vari-
ables on dependent variables and established reliability on
design of experiments in the optimization of nanosuspension
production. The ratio of polymer to drug and milling speed
were found to affect the ZP while the PS was found to be
affected by milling time and milling speed and accordingly,
the independent variables were optimized. Additionally the
authors claimed to have identiﬁed important formulation vari-
ables and production processing parameters which may affect
the nanosuspension production at higher scales. The inevitable
industrial scale manufacturing requirements like high polymer
concentration and high milling speeds which may be associated
with issues such as rise in production temperature and increase
in the pressure on the milling equipment were said to have been
met by modulating the milling speed and time. Milling at lower
speeds for the ﬁrst 10 min followed by a slow increase in speed
was attempted to meet the production level requirements. The
authors have not reported the production of any scaled up
batches. Hence, no note on the production level equipment
had been reported. Singare and his coworkers successfullyapplied this optimized method of production for the manufac-
ture of NCs of glyburide too (Singh et al., 2011). The applica-
bility of the optimized processing and formulation parameters
to another drug signiﬁes the robustness and quality of optimi-
zation achieved by these researchers.
4.3. Lab to pilot level upscaling of smartCrystal combination
technology for the manufacture of apigenin nanocrystals (Shaal
et al., 2010)
Apigenin NCs were produced at lab and pilot levels by apply-
ing a scale up factor of 150. 20 g product at lab scale was man-
ufactured by HPH and the production was scaled up to 3 kg at
pilot scale using CT (media milling followed by HPH), a
smartCrystal technology.
4.3.1. Process
Apigenin nanosuspension at lab scale was manufactured using
Micro LAB 40 (discontinuous mode) by applying 30 homoge-
nization cycles at 1500 bar pressure. The process characteriza-
tion revealed that the homogenization cycles beyond 20 had
little effect on PS but decreased the polydispersity index
(PDI). The 20 g lab product after 30 cycles showed a mean
particle size of 264 ± 5 nm and a PDI of 0.136 ± 0.05. The
reproducibility was checked with 3 batches. The production
at pilot scale employed CT technology where 3 kg product
was manufactured. The product was initially processed for 7
passages using pearl milling (discontinuous mode set up) and
was further processed by one cycle of HPH treatment with
Avestin C50 at 300 bar pressure. These operating parameters
were said to be ﬁnalized based on the initial screening studies.
At the end of 7 milling cycles, the product attained 440 nm PS
and 0.265 PDI. The subsequent homogenization yielded
product of PS 413 nm and PDI 0.2.
4.3.2. Equipment
The lab level studies employed Micro LAB 40 for homogeniza-
tion. At the pilot scale, the CT technology employed use of a
discontinuous mode set up of pearl mill and Avestin C50 HPH.
4.3.3. Formulation
The optimized formula contained 10% apigenin powder and
1% surfactant (Plantacare 2000) dispersed in puriﬁed water
as dispersion medium. The formula was maintained constant
at lab and pilot scales where 20 g and 3 kg products were man-
ufactured, respectively. However, during the pilot production,
the nanosuspension based on the above formula and operated
by pearl mill was diluted with 1% surfactant solution prior to
homogenization step.
4.3.4. Stability
Irrespective of the batch size and the production method
employed, all the samples at lab and pilot scales remained
physically stable with respect to ZP, PS and PDI during the
6 month long term study period carried out at 4 C, room tem-
perature and 40 C with no signs of Ostwald ripening (OsR).
The ZP values at lab level using HPH, LAB 40 were
38 mV in water and 37 mV in the original dispersion med-
ium (water and 1% surfactant solution). The ZPs recorded for
pilot batch were 45.0 mV in water and 42.5 mV in the
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Plantacare 2000 at 1% concentration seems to have sufﬁced
the stability (electrostatic and steric) requirement as conﬁrmed
by the ZP values studied. The particle size analysis was
performed by photon correlation microscopy (PCS), laser
diffraction (LD) and light microscopic (LM) studies. The
observations of all the three studies on the day of production
and at the end of six months of stability study at room
temperature indicated no signs of large crystals or visible
aggregation and depicted comparable results between lab
and pilot batches.
4.3.5. Summary
The authors successfully produced 20 g product at lab scale
and 3 kg product at pilot scale with comparable PS, ZP
and PDI. It was expressed that the discontinuous arrange-
ment of the CT (media milling followed by HPH), smartCrys-
tal equipment set up may assure the transferability to
production level for manufacturing few hundred kg product.
The study suggested few rules of thumb and interpretations.
The effect of pearl milling on the PS was found to be depen-
dent on the agitator rotation speed, the velocity of pumping
of suspension and the number of milling cycles. The PS
reduction by HPH was found to be inﬂuenced by the number
of homogenization cycles and pressure applied which could in
turn depend on the initial product hardness, crystalline and
amorphous fractions and the crystalline imperfections. It
was suggested that a pearl mill could handle higher drug con-
centration and could process 2–3 times more viscous macro-
suspensions in relation to a homogenizer. It was also
interpreted that the size of NCs obtained would in general
be 1000 times smaller than the employed milling pearls’ vol-
ume since the study employed 0.4 mm pearls and yielded
400 nm particles.
4.4. Design of a continuous and scalable process for the
development of a water redispersable nanocrystal formulation
(Hu et al., 2011)
The aim of this work was to develop a direct, fast, continuous
and scalable process for precipitating drug NCs. Fenoﬁbrate
was employed as a model low solubility drug for the produc-
tion of drug NCs. ‘Batch mixing coupled with spray drying’
was developed as proxy for ‘continuous static mixing coupled
with spray drying’. The former process was studied in this
research work in order to conﬁrm the feasibility of the latter
for large scale production of NCs. Based on the characteriza-
tion results of morphology, PS, crystalline state and drug
release, the batch mixing coupled with spray drying was
reported successful for the continuous NC production and
therefore, the potential of the model, ‘continuous static mixer
coupled with spray dryer’ was claimed. The authors previously
proposed the use of static mixer for the continuous production
of NCs by bottom up precipitation method (Dong et al., 2010).
As an extension of the above work, and in order to deal with
the OsR problem, the authors examined the effect of the sub-
sequent and immediate spray drying on the precipitated NCs.
Hence, the process developed for manufacturing was antisol-
vent precipitation combined with spray drying followed in a
continuous loop as opposed to the typical batch
manufacturing.4.4.1. Process
Though the original aim of authors was to couple the static
mixer with spray drier to achieve continuous production, for
the sake of lab level study, to avoid the production of large
quantities of NCs as obtained with the use of a typical static
mixer which would require a costlier spray dryer beyond the
lab scale capacity, the authors proposed the batch precipita-
tion process as a proxy for the continuous static mixing. The
PS of NCs obtained from the batch and static mixing was com-
pared to investigate the equivalence between the two methods.
Hence, the process involved immediate treatment of the batch
wise precipitated NCs with a mini spray dryer wherein dried
NCs were produced within 1 min.
Scaled up batches were not produced but the aim had been
to develop a manufacturing process which could be scalable.
Static mixing can maintain the same precipitation conditions
at any scale of study and therefore, the stirring and mixing
problems could be avoided at the production scale. Hence, a
combination of batch wise antisolvent precipitation (proxy
for continuous static mixing at production scale) coupled with
spray drier was proposed in this study.
4.4.2. Equipment
The authors employed magnetic stirrer (wherein the precipita-
tion was carried out multiple times with a new beaker of anti-
solvent each time) coupled to a Bu¨chi Mini Spray-dryer B-290
with inlet loop B-295, Germany for the continuous intake of
the product precipitated batch wise. The static mixer used
was 6-element SMV DN25 from Sulzer Chemtech,
Switzerland.
4.4.3. Formulation
For continuous looped batch wise production, 50 mg of fenof-
ibrate was dissolved in 1 ml of ethanol (solvent) which was
added at 1000 rpm stirring rate and at room temperature to
10 ml antisolvent (water) containing 10 mg/ml of lactose or
mannitol, 0.5 mg/ml of sodium dodecyl sulfate (SDS) and
0.5 mg/ml of HPMC E3. Thus obtained NCs suspension was
immediately spray dried.
For static mixing, the drug-solvent and antisolvent solu-
tions were pumped through nozzles of diameters 0.5 and
1.5 mm and at ﬂow rates of 50 and 500 ml/min respectively
into the 6-element SMV DN25 static mixer.
Field emission scanning electron microscopy and dynamic
laser light scattering studies conﬁrmed the nanosize of freshly
precipitated formulation as well as subsequently spray dried
and redispersed (in water) formulation. Powder-XRD, DSC
studies conﬁrmed the retention of crystallinity of fenoﬁbrate
in NCs. The PS results for NCs obtained by batch (magnetic
stirring) and static mixing were 318 ± 19 and 328 ± 22 nm,
respectively which conﬁrm the usage suitability of the
employed batch mixing process as a proxy for static mixing.
The freshly prepared NCs from batch mixing, when not sub-
jected to spray drying began to start growing in size to
2.5 lm within 10 min. Hence, an immediate spray drying step
was coupled with the precipitation step by batch mixing. The
release proﬁle of the developed (spray dried) NCs was com-
pared with sample 1 and sample 2 (described as follows). Sam-
ple 1 was a physical mixture consisting of 1 g of micronized
fenoﬁbrate, 2 g of lactose, 0.1 g of HPMC E3 and 0.1 g of
SDS, and mixed using a mortar and pestle. Sample 2 was a
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water. The dissolution studies showed that 84.2% of drug dis-
solved from NCs in 5 min as compared to 31.7% drug dis-
solved from the conventional spray-dried formulation
(sample 2) and 9.7% drug dissolved from the physical mixture
using micronized fenoﬁbrate (sample 1). The drug from NCs
completely dissolved within 15 min while 17% and 44% drug
remained undissolved in case of physical mixtures of micron-
ized fenoﬁbrate prepared with (sample 2) and without (sample
1) spray-drying, respectively, even after 60 min. The redisper-
sant used for spray drying was lactose or mannitol, both of
which showed similar results.
4.4.4. Stability
Stability was not studied and storage conditions were not
reported.
4.4.5. Summary
The static mixing set up mentioned in this work was initially
established by these authors for the production of spiranolac-
tone NCs. The experimental set up sufﬁcient to precipitate
the drug particles in the submicron range (of about 500 nm)
was optimized as SMV DN25 static mixer designed for turbu-
lent ﬂow which contained 6 mixing elements accommodating
a total ﬂow rate of 1.0 L/min where the ﬂow rate ratio of sol-
vent to antisolvent was maintained at 1:9. The increase in the
number of mixing elements to 12 was found to further decrease
the PS and size distribution. The increase in drug concentration
led to aggregation and an upper limit concentration of 10 mg/
ml could only result in sub micron particles. Further increase
in drug concentration did not yield nanosized product. The
spiranolactone nanosuspension freeze dried using lactose as
redispersant and cryoprotectant exhibited 6.6 and 3.3 times fas-
ter dissolution rate than the freeze dried raw drug formulation
(containing approximately 33% drug loading, 60% lactose,
3.3% HPMC and 3.3% SDS) in 5 and 10 min, respectively.
The optimized formula of NCs was not clearly disclosed. The
NCs exhibited a dissolution peak in 10 min in view of the
60 min study period. The XRD and SEM results demonstrated
that the freshly precipitated drug NCs formulation subjected to
immediate freeze drying was amorphous in nature while the
nanosuspensions left alone for several minutes before freeze
drying acquired crystalline state on their own and that crystal-
line state was in accordance to the raw drug (Dong et al., 2010).
In the current work (Hu et al., 2011), the production of fenof-
ibrate NCs was carried out by immediate spray drying of the
product precipitated batch wise using amagnetic stirrer (contin-
uously looped to spray drier). The morphology, PS, crystalline
state and drug release study results (as discussed in the formula-
tion section) revealed the successful use of this continuous pro-
duction process (proxy for the continuous static mixing). So,
based on the results obtained for the NCs of spiranolactone
and fenoﬁbrate, the plausibility of large scale production using
a combination of staticmixer and spray drier could be endorsed.
4.5. Particle sizing using a universal wet milling designs
applicable since discovery stage to the preclinical studies (Niwa
et al., 2011)
Miniature, middle and large scale wet milling designs were
developed which could be operable for drug loadings in therange of 50 mg to 30 g. The manufacturing level scale up
was not reported. This drug loading range would cover the
early screening studies’ requirement (10–100 mg) as well as
the late safety studies’ requirement (10–100 g). The designs
were basically developed to facilitate the economic use of time,
compound and investment. The solid state characterization
studies indicated that the crystal form and crystallinity of the
drug were retained after milling process. The milling designs
proposed in this research work may be applied by the scientists
as simple and easy techniques during the discovery phase since
the desired sub micron range particles could be produced in a
run time as less as 10 min. The milling designs differed only in
the nature of collision impact applied. At the middle scale,
oscillating beads-milling apparatus was used for which the
process operational conditions and the formula (type and com-
position of dispersing agents) were optimized so as to achieve
ﬁner drug particles. The mode of mixing employed at
miniature and large scales was stirring and turbulence using
a laboratory magnetic stirrer and a turbulent rotating shaking
mixer (turbulent mixer) respectively. The developed designs
may ﬁnd use in evaluating the poorly water soluble drug
candidates at discovery stage from the pharmacological, toxi-
cological and pharmacokinetic perspectives.
4.5.1. Process
At the middle scale, oscillating beads mill was operated using a
50 ml conical tube containing 0.6 g drug and 60 g zirconia
beads (making up around 16 ml volume of the tube) suspended
in an aqueous dispersion medium of 15 ml (40 mg/ml drug
concentration). The tube was placed into a holder and oscil-
lated at 2700 rpm for 12 min (optimized driving or running
time independent of drug loading) and the holder was cooled
by circulating a refrigerant to maintain a temperature under
15 C. A 12 min run time could produce particles in a nano
range for a drug concentration up to 100 mg/ml (1.5 g total
drug). The authors reported that the increase in run time pro-
duced nano sized particles with ease up to as high as 160 mg/
ml drug concentrations (data not presented). The milling
process was found to be inﬂuenced by the milling media (zirco-
nium beads) size and 0.3 mm beads were set as optimum after
trying the effect of different sizes (0.1–1 mm).
For miniature scale production using magnetic stirrer, the
same quantity ratio of the drug, beads and dispersion medium
(0.1 or 0.6 g drug was milled in 2.5 ml or 15 ml medium using
10 g or 60 g beads) as used in the middle scale was ﬁlled into
glass vials of 10 and 50 ml capacities. This suspension was
milled using 0.3 mm beads on the magnetic stirrer at
700 rpm for 24 h. 0.05–0.5 g and 0.6–3 g range drug loadings
were studied using 10 and 50 ml vials respectively.
For large scale manufacture, the turbulent mixer was
employed. A turbulent mixer mixes samples by rotating the
container with samples in planetary and twisting motion.
The drug loads in the range of 7.2–28.8 g of phenytoin were
studied. 570 ml steel bottle was ﬁlled with a 180 ml aqueous
medium containing drug and 720 g of 0.3 mm zirconia beads.
The bottle was rotated using the turbulent mixer at 96 rpm
for 90 min.
4.5.2. Equipment
Laboratory magnetic stirrer (HS4-SP, AsOne, Osaka, Japan),
oscillating bead mill (Multi-Beads Shocker, Yasui Kikai,
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Mixer T2F, Willy Bachofen, Basel, Switzerland) were used at
the miniature scale, middle scale and large scale respectively.
For morphology studies, all the samples were dried using
freeze-dryer, model PFR-1000/UT-2000, Tokyo Rikakiki,
Tokyo, Japan. For crystallinity studies, the samples from oscil-
lating bead mill were dried using a tray drier (DRA-630DA,
Advantec Toyo Ltd., Tokyo, Japan) as well as freeze drier
(RLE-52, Kyowa Vacuum Engineering Co., Ltd., Tokyo).
4.5.3. Formulation
Phenytoin was used as a model bcs class 2 drug. Additionally,
nifedipine and pranlukast hydrate were also formulated using
the middle scale design to generalize the signiﬁcance of the
approach, conﬁrm its robustness independent of the physico-
chemical properties of drugs and to expand its application.
The preparations were subjected to particle size analysis, zeta
potential, morphology and crystallinity studies (tray dried
and freeze dried products were subjected to XRD and DSC).
The SEM photographs gave visual conﬁrmation of milling in
the nano range. The XRD and DSC studies conﬁrmed the
retention of crystallinity in all the processed samples.
The milling process was found to be inﬂuenced by the
choice of dispersing agents and as such their composition
was ﬁnalized as 0.5% polyvinylpyrrolidone (PVP) as steric sta-
bilizer and 0.1% SLS as electrostatic stabilizer which resulted
in zeta potential of 30 mV required to stabilize the colloidal
particles. Use of different surfactants and stabilizers and trials
of milling without addition of stabilizers ﬁltered the above
mentioned combination as optimized dispersing agent compo-
sition. The results also indicated that the size reduction
through wet milling could be attributed not just to the mechan-
ical stress but also to the drug molecular interactions with the
dispersing agents.
Milling performance using three model drugs (phenytoin,
nifedipine and pranlukast) was studied only at the middle scale
using oscillating beads-milling apparatus. The particle size of
the starting material of nifedipine was larger compared to that
of phenytoin while that of pranlukast was smaller. The study
indicated that irrespective of the compounds and their original
particle sizes employed, the milled particles reported the parti-
cle size distribution (PSD) at around 0.3 lm and 180 nm when
analyzed with laser diffraction and dynamic light scattering
methods, respectively. Not only that the nanometric range pro-
duction was conﬁrmed but the PSD was also found to be quite
narrow and nearly monodipersed.
The formulations manufactured using the lab magnetic stir-
rer and with drug loads in the range of 50–400 mg (in 10 ml
vials with 2.5 ml aqueous media) showed PSD results in submi-
cron range equivalent to those produced by the middle scale
apparatus. The studies in 50 ml vials yielded similar results
for 0.6–2.4 g of phenytoin.
Regardless of the milling mechanism applied at different
scales, 160 mg/ml drug load is the maximum concentration
of drug that could be nano-milled with reproducible and
robust PSD results. Authors reported with practical results
that 28.8 g of phenytoin could be effectively treated as a
maximum amount using the employed turbulence mixer while
further scale up experiments were yet to be done.
Nanosized particles in the range of 200–400 nmwere success-
fully prepared with variable drug loads in the range of 10 mg to10 g independent of the equipment used. 95%of drugwas recov-
ered and the drug loss was accounted to the adhesion of particles
to the container walls and beads. Independent of the drug loads
and manufacturing equipment, 0.5% PVP + 0.1% SLS combi-
nation in the aqueous solutionwas found to serve as efﬁcient dis-
persing medium. The redispersion of formulations upon drying
and the dissolution properties were not studied.
4.5.4. Stability
Stability studies were not reported in the publication under
discussion.
4.5.5. Summary
The authors successfully designed universally applicable wet
ball mill designs for evaluating the poorly water soluble drug
candidates ever since the discovery stage (early screening stud-
ies) till preclinical stage (late safety studies) from the pharma-
cological, toxicological and pharmacokinetic perspectives.
Laboratory magnetic stirrer, oscillating bead mill and turbu-
lent rotating shaking mixer were used at the miniature scale,
middle scale and large scale respectively. The proposed ball
mill designs would be operable covering drug loadings in the
range of 50 mg to 30 g. The study indicated that irrespective
of the compounds and their original particle sizes employed,
the milled particles reported nanometric PSD results which sig-
niﬁes the universal applicability of the approach and conﬁrms
its robustness independent of the physicochemical properties
of drugs. Additionally, the results also indicated that the size
reduction through wet milling could be attributed not just to
the mechanical stress but also to the drug molecular interac-
tions with the dispersing agents which emphasizes the coordi-
nated role of process, equipment and formula in the success of
a pharmaceutical design.
4.6. Preparation of nevirapine nanosuspensions at lab and pilot
scale levels by high pressure homogenization and media milling –
a comparative study (Shegokar et al., 2011)
This work produced redispersible white colored homogenous
nanosuspensions of pH between 6.87 and 7.02 at three differ-
ent scales. The PSD analysis conﬁrmed that the manufactured
particles were below 5 lm which makes the formulation
suitable for intravenous (IV) administration.
4.6.1. Process
Three batches at lab (40 ml), medium (2 kg) and pilot scales
(150 ml) were produced using piston gap homogenizers at
lab and medium scales and using a bead mill at pilot scale.
A coarse suspension was premixed and subsequently processed
using HPH or bead mill.
At lab scale, 40 ml nanosuspension was processed using
Micro Lab APV 40. Premilling was carried out for 2 cycles
at each of the 200, 500, and 1000 bar low pressures followed
by actual homogenization for 20 cycles at 1500 bar. The
homogenization tower was maintained at 4 C all through
the processing period and the formulation was cooled after
each 5 cycles. The relation between the decrease in PS and
the increase in homogenization cycles remained linear till 15
cycles after which the further increase in the number of
homogenization cycles had not favored any further reduction
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white nanosuspension with a mean PS of 481 ± 10 nm and
PDI of 0.212 ± 0.085.
At medium scale, 2 kg coarse suspension was homogenized
for 30 min in continuous mode using EmulsiFlex C50 or Aves-
tin C50. The homogenization tower was pre cooled at 4 C by
passing ice cold distilled water and during the processing per-
iod, the nanosuspension temperature was controlled using
water bath. 30 min processing using Avestin C50 at 1500 bar
pressure (without any premilling) yielded nanosuspension of
PS 429 ± 16 nm and PDI of 0.158.
At pilot scale, 120 ml coarse suspension of nevirapine was
milled using Bu¨hler PML-2 bead mill at 1000 rpm and 4 C.
The mill was run in continuous mode for 3 h and the medium
employed for milling was 0.2–0.4 mm yttria stabilized zirco-
nium oxide beads. At the end of 3 h, the mean PS obtained
was 202 ± 12 nm and PDI of 0.182 ± 0.093.
4.6.2. Equipment
The equipment used for lab scale, medium scale and pilot pro-
duction were Micro Lab APV 40, Avestin C50 (piston gap high
pressure homogenizers) and Bu¨hler PML-2 bead mill
respectively.
4.6.3. Formulation
2% w/w coarse nevirapine powder was dispersed in 2.8% w/w
aqueous surfactant solution. The 2.8% surfactant solution was
made up using 1% tween 80, 0.9% volpol4, 0.5% poloxamer,
0.3% PVP and 0.1% plasdone. A premixed coarse suspension
was processed using HPH and bead mill. The drug content as
low as 2% was said to have been used in order to achieve max-
imum possible PS reduction to suite IV administration. The
formulation was characterized for mean PS, PDI and ZP. PS
and PDI were observed using PCS, LD and LM. ZP was mea-
sured in water and in original surfactant solution. All the ZP
values were around 15 mV. The XRD studies conﬁrmed
retention of crystalline character.
4.6.4. Stability
12 month long term stability was performed at 4 C, room
temperature and 40 C. The particle size was analyzed at the
end of one year which suggested formation of aggregates
and hence physical instability, particularly for the HPH pro-
cesses. The WBM processed product as well showed an
increase in mean PS from 210 to 669 nm at the end of one year.
4.6.5. Summary
The authors conveyed that the 15 mV ZP values could sufﬁce
the stabilizing requirement of nanosuspension since they claim
that the general rule of ±30 mV ZP requirement would be
applicable only in case of electrostatic stabilization and that
the inclusion of steric stabilizers may stabilize the particle sur-
face even at ZP values as low as 15 mV. However, the phys-
ical instability reported at the end of one year conﬁrms the
instability of formulation. The stabilizer system and composi-
tion may require alteration and optimization. Further, the
authors opted air drying of nanosuspension with no data
reported about the method. Freeze/spray/ﬂuid bed drying, if
applied, may have enhanced the stability of formulations.
Though the product was scaled up by a factor 50 using HPHs(homogenization yielded products with comparable PS, PDI,
and ZP values), the stability proﬁle was not acceptable. The
authors, however, ﬁnally conﬁrmed the scalability of milling
process (for IV administration purpose) by also referring to
one of their previous works on apigenin which involved appli-
cation of a scale up factor of 150. They conveyed that the use
of bigger milling chamber, transfer from continuous mode to
discontinuous mode of milling and application of 6–7 milling
cycles could process up to 20% solid content and render a
robust product (with only a few changes in the nanometer size
of particles).
4.7. In-vitro and in vivo evaluation of nitrendipine nanocrystals –
a miniature scale up study (Quan et al., 2011)
Nitrendipine NCs for oral delivery were prepared by precipita-
tion-homogenization and by subsequent spray drying. The
production was successfully scaled up from 20 to 300 ml.
4.7.1. Process
The nanonization process employed was precipitation fol-
lowed by homogenization. 100 mg/ml solution of nitrendipine
in acetone was dispersed in water containing 1 mg/ml polyvi-
nyl alcohol at 10 C. The drug solution concentration and tem-
perature were the parameters optimized for precipitation
process. The increase in nitrendipine concentration in acetone
from 100 to 120 mg/ml was reported to increase the PS and
span values. The temperature for precipitation process had
been optimized at 10 C since the increase in temperature leads
to crystal growth. The parameters, pressure and number of
homogenization cycles of HPH process were optimized as
1000 bar and 20 cycles respectively. While the particle size
decreased with increasing HPH pressure, it increased with
increasing cycles. The processing conditions, 20 homogeniza-
tion cycles and 1000 bar pressure yielded smaller PS with a
lower span value. The homogenization of presuspension
yielded NCs of 175 ± 13 nm mean PS with a span value of
0.9766 ± 0.1658. The NCs were dried by spray drying process
and the production was successfully scaled up from 20 to
300 ml.
4.7.2. Equipment
The equipment used for carrying out precipitation was not
described. The homogenization was performed using piston-
gap homogenizer, ATS AH100D model and spray drying
was done using SD-1000 spray-drier, Eyela, Tokyo, Japan.
4.7.3. Formulation
100 mg/ml of nitrendipine in acetone was dispersed in water
containing 1 mg/ml polyvinyl alcohol. Acetone was used as
solvent, water as antisolvent and polyvinyl alcohol was
employed to inhibit the unwanted crystal growth during the
HPH step. Only 300 ml batches were spray dried for which car-
riers like lactose or mannitol were added by dissolving in sta-
bilizer solution before precipitation. The carriers were reported
to have a great inﬂuence on the dried powder ﬂowability rather
than on the PS. The carrier concentration at 1.7% ensured a
reproducibly redispersable formulation although there were
slight differences between the non-dried product and redi-
spersed spray dried product. The DSC, XRD studies of initial
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retention of crystalline character with no change in glass tran-
sition temperature of nitrendipine. Lyophilized sample (with-
out carrier) was used as control for XRD studies for testing
the spray dried samples in which, mannitol’s diffraction pat-
tern interfered with that of the drug. The comparison of
in vitro dissolution proﬁles of the NC formulation, physical
mixture and commercial tablet showed that NCs released
100% drug within 1 min while physical mixture and commer-
cial tablet released only up to 9% and 55% of drug in 1 min.
Even after 10 min, the physical mixture and commercial tablet
released only 40% and 90% drug respectively.
The in vivo bioavailability was studied in rats by HPLC
which concluded that NCs showed 15- and 10-fold greater
Cmax and 41- and 10-fold greater AUC0ﬁ24 than the physical
mixture and commercial tablet, respectively. While the differ-
ence in the elimination rate constant values observed for
NCs, physical mixture and commercial tablet remained statis-
tically insigniﬁcant, the relative bioavailability values of NCs
and physical mixture in relation to the commercial tablet were
1018.98% and 24.57%, respectively.
4.7.4. Stability
The stability studies were not reported. However it has been
mentioned as authors’ observation that the NCs retained their
PS constantly and exhibited good redispersibility over a
storage period of 1 year under ambient conditions.
4.7.5. Summary
The current research work employs a combination technology
to produce NCs wherein the bottom up precipitation was fol-
lowed by top down HPH. Nanoedge is an example of tech-
nology which involves microprecipitation plus HPH for the
production of drug NCs. The authors successfully produced
up to 300 ml volume of nitrendipine NCs which presented
superior in vitro dissolution and in vivo pharmacokinetic pro-
ﬁles compared to the physical mixture and commercial tablet.
4.8. Nanosuspension production by wet ball milling: optimization
of process parameters and formulation variables (Ghosh et al.,
2012)
In this particular work, the production parameters for scale up
were optimized with respect to two equipments (a screening
purpose planetary mill and a lab scale stirred media mill).
The scale up factor for the volume of nanosuspension manu-
factured was however not reported.
4.8.1. Process
The wet ball milling process employed for the production of
nanosuspension was optimized for process parameters as fol-
lows. A 23 factorial design of experiments and the knowledge
and experience from the previous studies were applied to study
the effect of variations in drug content (2%, 5%), milling
media size (0.1 mm, 0.5 mm of yttrium stabilized zirconium
beads) and mill rotation frequency (150 rpm, 400 rpm). The
milling beads size and rotation frequency of mill were opti-
mized as 0.2 mm beads (this number, though was not studied
as variable, was optimized since the experimental design and
outcomes of previous experiments suggested that at higherrpm, the bead size would be the least signiﬁcant parameter)
and 400 rpm respectively for scale up studies. The total milling
time was ﬁxed as 4 h for all the trials.
4.8.2. Equipment
The production scale up was attempted with respect to the
equipment design optimization (similarity). The agitation rates
were correlated for two equipments by conducting the bridging
studies. Screening experiments were performed in planetary
mill (early development phase). After optimizing the critical
process parameters and formulation variables, the ﬁnal variant
was produced in a lab scale stirred media mill, Lab Star with
zeta agitator in recirculation mode (lab scale development
phase). The principle of agitation was different for the equip-
ments. The agitator was a rotating jar in the planetary mill
while it was an impeller in the Lab Star. The bridging studies
concluded that 2500 rpm run in Lab Star would equal a
400 rpm run in the planetary mill to achieve similar particle
sizes. All the formulations designed for the in vitro and
in vivo studies were manufactured using Lab Star with the pro-
cessing temperature maintained at 35 C (temperature main-
tained by circulating cooled water through the outer jacket
in a controlled fashion). The agitating speed was 2500 rpm
and the pump speed was 250 rpm. Also once the bridging
was done, the grinding efﬁciency was evaluated (based on PS
results) by comparing the performance of the two mills by ana-
lyzing the samples collected at different time intervals. The
results showed insigniﬁcant difference with respect to the PS
values obtained with the two mills.
4.8.3. Formulation
The batch size was 25 ml for the preliminary phase of research
carried out using planetary mill. The formulation variables like
the drug content, ratio of drug:surfactant and type and con-
centration of additional surfactants were optimized. Com-
pound NVS-102 was used as the model drug. D-a-tocopheryl
polyethylene glycol 1000 succinate (TPGS) was used as surfac-
tant. 23 factorial design was applied to optimize the drug con-
tent. 5% drug content in suspension, 2:1 drug:TPGS ratio
along with 1% HPMC (3 cps) were ﬁnalized as efﬁcient to
design a robust and stable formula. However the same formula
manufactured by Lab Star yielded PS < 300 nm for one batch,
F2 for which the sample was collected 1 h after milling and
PS < 750 nm for another batch, F3 for which the sample
was collected at the end of 4 h of milling and these batches
were studied for stability and in vivo performance. Addition-
ally, F2 presented narrower PSD and the PSD for F3 was
broader. The dissolution studies showed that F2 and F3 pre-
sented superior dissolution proﬁles in relation to the unmi-
cronised samples while F2 and F3 had similar release proﬁles.
The unmicronised control batches as well as unmicronised
batches with similar formula as F2 and F3 showed inferior
(statistically signiﬁcant) AUC and Cmax data compared to F2
and F3 emphasizing that the improvement in bioavailability
could be attributed notably to nanonization alone. Addition-
ally, the individual plasma concentrations conveyed that
NCs of F2 with smaller PS and narrow or homogeneous
PSD produced less variability compared to F3 possibly due
to minimal instances of OsR with F2 (though the dissolution
proﬁles of F2 and F3 were similar). Though statistically insig-
niﬁcant, the AUC and Cmax of F2 increased by 16% and 28%,
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narrow PSD as well.
4.8.4. Stability
The stability studies were performed at 2–8 C for 6/12 weeks
storage time. PS analysis was performed at the end of
6/12 weeks which indicated that the crystal growth was
minimum during the storage period (though there was a slight
increase in the mean PS values, the statistical signiﬁcance was
not reported). F2 showed superior stability compared to F3
with most minimal instance of OsR.
4.8.5. Summary
During the early development phase, nanosuspension was
manufactured using planetary mill for screening purpose.
Experimental design was applied to optimize the formulation
aspects. Later, a bridging study was conducted and product
performance similarity was successfully achieved between the
planetary mill and lab scale stirred media mill by optimizing
the equipment operation conditions. All the formulations for
in vitro and in vivo testing were produced using media mill
with zeta agitator in recirculation mode. Finally, based on
the in vitro drug dissolution and in vivo pharmacokinetic stud-
ies, it was concluded that the prepared nanosuspension pre-
sented enhanced dissolution and bioavailability proﬁles.
5. Upscaling of NCs: challenges and handling
Gradual movement from small to larger scales may generate
unanticipated new problems at any stage of development.
However, the success of scale up lies in reproductive yielding
of a robust product conﬁrming to its quality speciﬁcations,
irrespective of the scale of study. The experience at the lab
and pilot plant scale levels could be an additional asset at pro-
duction or commercial scale. Understanding of the process
parameters becomes mandatory and scale up issues further
demand the joint attention of pharmaceutical formulators
and engineers. Such an understanding is, however, a challeng-
ing task since the list of inﬂuential parameters to be scrutinized
at the lab level does not always remain the same when it comes
to dealing with a production plant process. The plan for scaleFigure 3 Various considerations assocup commences ever since making the choice of technology
which may depend on the indications of the ﬁnal formulation,
dose and route of administration. Each manufacturing tech-
nology has its own unique impact on the pharmacokinetic pro-
ﬁle of the therapeutic agent and a slight manipulation of any
given technology yields a signiﬁcant difference in the pharma-
cokinetics of the ﬁnished product. The difference in pharmaco-
kinetic proﬁles may be largely due to the differences in the size
of the NCs obtained with different methods. Hence, the deci-
sion making at the early stages of formulation development
always demands the involvement of scientists equipped with
tools of drug delivery, fundamental understanding and past
knowledge. The choice of technology (Fig. 3) should consider
the target drug proﬁle, optimal patient beneﬁt, technical issues
(differences in bioavailability and pharmacokinetic studies),
economical aspects (frontloading, manufacturability and mar-
keting) and the intellectual property rights (IPR) wisdom (non-
infringement of patents).
Many of the challenges during upscaling studies could be
met by emphasizing on four basic parameters namely process
characterization, choice of equipment, development of robust
formulation and stability studies, ever since the formulation
development stage (Fig. 4) (Levin, 2002).5.1. Process characterization and choice of equipment
The variations applied and observed in equipment (scales),
process (modiﬁcations), and product (quantities) during the
process of scale up complicate the task of scale up. The param-
eters to be controlled and monitored differ starting from the
material handling (viscosities encountered and heat dissipation
capacities of the systems), ﬂow rates and shear stress to the
storage and transfer levels. The effects of all these variations
adopted in the process of scale up may in combination and/
or with potential synergy yield the outcome of scale up beyond
any prior expectations and experiences. The formation of NCs
is governed by various rates such as the rate of addition of sol-
vents, rate of shearing, rate of mixing, rate of subdividing and
the rates of solvent removal and pumping. The knowledge of
individual unit operations of a manufacturing process, the
physical and physicochemical aspects of each of the operation,iated with the choice of technology.
Figure 4 Basic quadrupole prerequisites for successful scale up
of nanocrystals.
400 K.M. Raghava Srivalli, B. Mishraand the interactions among the components of process
becomes mandatory. If the unit operation mixing is considered
for instance (say, the precipitation method of preparation), the
lab and industry offer a bewildering array of choices for mix-
ing equipment. The dynamic components of mixing devices
may be stirrers at lab scale which transform into impellers of
different forms such as blades, paddles, propellers at higher
scales. In addition, the mixing efﬁciency still could be varied
by varying the number of impellers, impeller location, number
of blades per impeller etc. For a given formulation, since the
phenomenon of vortex formation is common with large tanks
than the small tanks, the full scale production is likely to
require bafﬂes while lab level does not. Additionally, since
the time required for executing a unit operation increases with
upscaling, the temporal effects need to be studied by and large.
It is to be noted that the lab scale equipment presents higher
surface area to volume ratios while the production level equip-
ments presents a higher volume to surface ratio. This differ-
ence is one of the considerable factors which slows down the
processing during scale up. The ﬁnite time required for an
operation at lab gets redeﬁned while scaling. For the given
extent of heat dissipation (heating and cooling), large scale
equipment consumes more time when compared to lab equip-
ment. These long processing times are likely to lead to adverse
conditions such as adsorption, precipitation, viscosity altera-
tions and may affect the mass and momentum transfer rates,
the shear rate and stress factors. Hence, the temporal effects
on the product’s physiochemical stability also require a guard-
ianship. The basic idea of study plan should always be to use a
scalable ‘smart experimental set up’ or the standard equipment
similar to that at production so that the processes and equip-
ment could later be scaled to larger batch sizes and also to
identify since the earlier stages, the critical process parameters
and dimensions.
Equipment upscaling concerns are fundamentally based on
preserving similarities. Geometric similarity requires a three
dimensional point to point correspondence between two sys-
tems. It is concerned with the linear dimensions of the two sys-
tems in question, the previous small scale (lab/ pilot) systemand the current scaled up system. The consistency in the ratio
of their linear dimensions assures geometric similarity. The
mechanical similarity describes the status of application of
force to a stationary or moving object and is deﬁned in terms
of the static, kinematic and dynamic similarity of the process-
ing equipment. Static similarity correlates the deformation
under constant stress of one system to that of another. If the
two systems of different sizes in addition to being geometri-
cally similar exhibit an equal ratio of velocities between corre-
sponding points, they are said to have kinematic similarity.
Dynamic similarity is attested when the two systems, small
scale and scaled up besides passing geometric and kinematic
similarities additionally present the same ratio of forces (grav-
itational, pressure, centrifugal) between corresponding points.
Thermal similarity is established by comparing the thermal
ratios of heat ﬂuxes by convection, conduction, radiation
and bulk transport. Thermal ratio is assured when the quantity
of heat transferred per unit time is constant for the two systems
under study. For systems in motion, thermal similarity
requires attainment of kinematic similarity. Chemical similar-
ity refers to the degree of the point to point variation in chem-
ical composition of the systems as a function of time and it
presumes the attainment of kinematic and thermal similarities.
Two systems under investigation are said to be chemically
similar if they have comparable concentration gradients as a
function of time. The choice of equipment should consider
the ﬁnal dosage form requirements of administration. In
general, the PS obtained from HPH process could be more
suitable for oral application and that obtained from milling
could suit parenteral application because of the smaller parti-
cle sizes achievable with milling (Lieberman, 1998; Shegokar
et al., 2011; Moeschwitzer, 2010a).
5.2. Robust formulation and stability
Pharmaceutical formulators, not surprisingly tend to initiate
the formulation development with a trial-and-error method
since serendipity has a huge role to play in the pursuit of a suc-
cessful scale up. However, in order to understand the statistics
of the literature or the compiled experimental data and to
understand the physics behind the problem, the application
of trial and error experimental methods becomes a necessity.
Experimental designs are in great demand in the current sce-
nario to handle the formulation development process and to
arrive at a rational formulation. The trial and error experimen-
tal approach before the start up and the design based experi-
mentation in the subsequent phase equips the formulator
with certain practical experience which is a prerequisite to
the further creative proceedings. Design of a robust formula-
tion at lab and pilot levels is vital to proceed with scale up
study. Development of a robust formulation for the produc-
tion scale is a further tedious process since the formula robust
at the lab scale may or may not serve the purpose at the higher
scales. This is because the mere application of the scale up vol-
ume ratio concept does not result in the same quality product
at production level. Regeneration or alteration of the model
developed at lab scale tends to be inevitable unless in cases
of luck and serendipity. The whole experimental work may
require a repetition at every scale of study and accordingly
new optimums need to be derived for the variables. Response
surface methodologies and the like could be used to compare
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required results (Faure et al., 2001).
Shelf stability is crucial to reap maximum biological bene-
ﬁts of the nanoproduct. Performing short term stability studies
at 5 C or 25 C and ensuring minimal changes in the particle
size, particle size distribution and zeta potential (ZP) for at
least one month will sufﬁce to prepare a nanosuspension for-
mulation for preclinical testing. Drug nanoparticulate formu-
lations could be studied for long term stability at 40 C,
room temperature and refrigeration and analyzed for their typ-
ical properties. They could be characterized for single NC
properties like particle size, zeta potential and drug loading
abilities as well as bulk properties like viscosity and redispers-
ability (wherever applicable) (Mishra et al., 2009; Cerdeira
et al., 2010). At every stage of study, the noted list of observed
changes needs to be evaluated to identify the cause for instabil-
ity. The drug expulsion, crystal formation, aggregates or crys-
tal growth investigation and the related study needs to be
performed to account for the causes like OsR. Stability of
NCs is affected by a variety of factors such as nature of drug
(small molecule or large biomolecule), delivery route (IV, oral,
inhalation or others), dosage form (liquid formulation or dry
solid), production technique (top down, bottom up or combi-
nation), manufacturing conditions (pressure and temperature),
dispersion medium (aqueous or non aqueous), storage and
shipping conditions. However, one unanimous consideration
is that dry powder formulations have limited stability issues
(Kipp, 2004).5.3. Miscellaneous parameters
Nanoparticulate system is a kind of formulation where the size
has it all to do with its properties and unique applications and
scale up is a process which as such alters the performance of an
operation. So the maintenance of particle size, size distribution
and polymorphism poses a particularly big challenge. When-
ever spray, freeze or ﬂuid bed drying is involved in drying
the nano sized product for producing a ﬁnished solid dosage
form, the drying effects are to be paid sufﬁcient attention to
retain the beneﬁts of nano sizing. The ﬁnal processed formula-
tion should not only ensure the complete release of the stable
nanoproduct in biorelevant media but also that the particle
size proﬁle is retained. Variations in the particle size, size
distribution of the formulation and the polymorphism of the
API alter ﬁnished drug product’s in vitro and biological
performance. When polymorphism is an issue associated with
the API in question, scientists need to produce NPs of consis-
tent size and polymorphic form since polymorphs of an API
are compounds with differences in their crystal packing struc-
tures as well as bioavailability proﬁles. So it has to be ensured
at the lab level itself that you have a good control over the
manufacturing operation in practice and the form of
polymorph attained. The ﬁnal target is always to produce an
ideal nano sized formulation with narrow particle size distribu-
tion and an ideal and reproducible polymorph wherever
applicable.
Literature conveys that polymorphic transitions have not
been prominently reported with WBM since most often, it is
the heat generated during processing which induces the crystal
modiﬁcations and in wet media milling, the process uses water
which effectively dissipates the generated heat. Further themilling process is carried out under controlled temperature
conditions. However performing basic analytical tests before
and after the processing will ensure the chemical integrity of
the compounds (Merisko-Liversidge et al., 2003). The licensed
and regulatory approved products already launched in the
market attest the capability of WBM process in maintaining
the appropriate polymorphic form of the processed API’s.
All the commercialized products contained actives with melt-
ing points ranging from 80 C to >200 C but as the WBM
is performed under controlled conditions, the polymorphic
transitions could be eliminated and/ or controlled. Thus the
formulation could be optimized with the desired polymorphic
form using WBM (Merisko-Liversidge and Liversidge, 2011).
The solid–solid morphology and crystal habit transitions
are the phenomena that are widely observed with precipitation
technique. When bottom up precipitation is used for manufac-
turing, the polymorphic form is inﬂuenced by processing
parameters, type of solvent-antisolvent-stabilizer combination
and super saturation degree. Hence the form could be altered
by changing the solvent types and modulating the degree of
super saturation. But a reproducible and desirable form of
polymorphic state is crucial for regulatory approval. Addition-
ally the content of residual solvent during precipitation process
should conform with the limit of residual solvents as per ICH
guideline Q3C. When a compound is subjected to transition in
polymorphic state, it becomes critical to identify the processing
conditions which can maintain the compound in the preferred
polymorphic state. The solid state characterization to study the
amorphous or crystalline nature and the crystalline forms of
nanonized compounds could be carried out by analytical test-
ing methods such as FTIR, DSC, XRD and NMR at every
stage of processing and formulation development. The general
notion is that the solid state forms with highest energy and
lowest melting point exhibit the best solubility. But any system
at high energy state will tend to lose energy and acquire a lower
and stable energy state. Therefore amorphous state though
increases saturation solubility, it is still a metastable state with
higher energy and may transform to a lower energy stable state
during shelf life. Solvent removal and formation of dried solid
powder can solve this problem. Amorphousness during the
process of precipitation is observed because the molecules get
less time to organize themselves in order. Sometimes the sol-
vent molecules may get entrapped into the drug molecules
and induce solvomorphism. The analytical testing methods
employed should also characterize the prevalence of polyamor-
phism (existence of the same chemical substance in different
amorphous forms) associated with the nanoproducts produced
by precipitation techniques. However, the crystal lattice
arrangement is an intrinsic property of an API. Thermody-
namically, albeit crystalline form is at the lowest, free and sta-
ble energy level, some molecules (ibuprofen) always precipitate
as crystalline forms irrespective of the solvents used whereas
other molecules (cefuroxime axetil) always tend to precipitate
as amorphous forms (Sinha et al., 2013; Sharma et al., 2011).
It has also been noticed that the morphology of nanoparti-
cles has its own distinguished effects on the drug bioavailabil-
ity (Venkataraman et al., 2011). The crystal morphology and
shape could be more qualitative aspects of nanocrystals rather
than polymeric and lipid NPs. The shape and size of the nano-
crystals could be determined by the morphology of the initial
crystal material, the plane of fracture of crystals and the
drug-stabilizer interactions. If the shape of the initial crystal
402 K.M. Raghava Srivalli, B. Mishramaterial is spherical, the drug nanoparticles could be nano-
sized from 10 microns to 200 nm range with a 50-fold increase
in surface to volume ratio (Merisko-Liversidge et al., 2003).
Strategic control of crystal morphology and shape is by and
large an expertise of precipitation techniques (bottom up
approaches) and is a face of research which is yet to be
explored effectively. Investigations have commenced in this
area to identify the beneﬁts of controlling the crystal morphol-
ogy and shape of drug nanoparticles. If positive effects on
nanoproduct stability and biological performance could be
unearthed, it would be really interesting. The molecular trans-
port of solutes induced by the change in process temperature
and viscosity of the medium (high drug concentrations) can
affect the morphology of ﬁnal nanocrystal product. High tem-
peratures and drug solution concentrations are known to yield
fragile and spherical particles. Literature reports that morphol-
ogy could be altered by changing the stabilizer type too. For
example, PVP (polyvinyl pyrrolidone) with SDS (sodium
dodecyl sulfate) yielded rod shaped particles and PEG (poly
ethylene glycol) with SDS yielded irregular ﬂake shaped parti-
cles (Sinha et al., 2013).
6. Conclusion
The ease of their manufacturing makes NCs the choicest nano-
particles if one needs to check the existence of any correlation
between the particle size and drug candidate bioavailability at
the discovery phase and initial screening stages. Such feasibil-
ity makes an NC formulation a rationale development. The
drug NCs being unique nanoformulation options with notable
advantages, the researches encompassing scalable formula-
tions/methods for the production of drug NCs open a new
vista and pave a new platform for the design of these nano-
pharmaceuticals. An analysis of the NC research works which
either had scalability as their objective or upscaling as their
future scope leads to our understanding that few authors
applied the same approach for the production of NCs at differ-
ent scales of study and claimed the signiﬁcance of similarity
preserving equipment. Few others employed different
approaches at different scales and therefore used different
equipment for producing different scales of products. Few
authors uniquely attempted the design of custom made appa-
ratus like a 3-way nozzle model for the production of NCs
in a continuous and scalable fashion. While the importance
of quality by design in the scale up studies was realized by
some authors, prolonged shelf life of ﬁnished product aided
by the incorporation of stable excipients was proposed by
some others. Still few other researchers included the trend of
studying the in vivo pharmacokinetics of their scaled up for-
mulations. It was understood that a successful scale up
demands an adequate process characterization, proper choice
of equipment, development of a robust formula and satisfac-
tory stability study results.
7. Future scope
Irrespective of the scale up targets achieved by the discussed
research works, each of such work had been a fruitful attempt
to gain beneﬁcial knowledge to carry out future upscaling
attempts in the ﬁeld of NCs. In a nut shell, it could be pro-
posed that a successful scale up demands an adequate processcharacterization, proper choice of equipment, development of
a robust formula and satisfactory stability study results
(Srivalli and Mishra, 2014). It was understood that process
characterization is required for ﬁltering the processing param-
eters inﬂuencing the product quality; the design of equipment
at different scales of study should ensure the consistency in
product quality; a robust formulation incorporating proper
choice of stabilizers and redispersants is a must to retain the
stability of the product all through its shelf life; and stability
studies are imperative to determine the stability of the product
and to predict its shelf life. More studies based on the scale up
of NCs are expected to be taken up by the researchers so as to
take an advantage of the product line extension offered by
FDA for these products. Future upscaling studies on NCs
may incorporate the in vivo studies on animals as a deﬁnitive
part of their formulation characterization.
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